BioLineRx (BLRX) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 18, 2021 7:00 AM EST- Positive results from pharmacoeconomic cost effectiveness study of Motixafortide in stem cell mobilization support its use as standard of care in combination with G-CSF -
- Pre-NDA meeting with FDA set for mid-December; NDA submission planned for H1 2022 -
- Cash and cash equivalents at September 30, 2021 of $62.2 million -
- Management to hold conference call today, November 18, at 10:00 am EST -
TEL AVIV, Israel, Nov. 18, 2021 /PRNewswire/ --Â BioLineRx Ltd. (NASDAQ: BLRX) (TASE:... More
